Author

F.-C. Hsu

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Meyers· 1 shared A. P. Khandhar· 1 shared C. Furdui· 1 shared C. McCall· 1 shared C.-M. Chuang· 1 shared E. Boudyguina· 1 shared G. D. Shimberg· 1 shared I.-M. Shih· 1 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Meyers

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

RNA-based vaccine demonstrates prophylactic efficacy against Mycobacterium tuberculosis challenge in a mouse model

S. E. Larsen, J. H. Erasmus, V. A. Reese, T. Pecor, J. Archer, A. P. Khandhar, F.-C. Hsu, S. G. Reed, S. L. Baldwin, R. N. Coler

This study evaluates two TB vaccine platforms in mice, showing both reduce bacterial burden, with RNA-based vaccines showing greater efficacy in combination immunization strategies.

bioRxiv · Feb 23, 2022 · PreprintImmunology

Hematopoietic-SLC37A2 deficiency accelerates atherosclerosis in LDL receptor-deficient mice

Q. Zhao, Z. Wang, A. Meyers, J. Madenspacher, M. Zabalawi, E. Boudyguina, F.-C. Hsu, C. McCall, C. Furdui, J. Parks, M. Fessler, X. Zhu

This study shows that hematopoietic SLC37A2 deficiency accelerates atherosclerosis in LDL receptor-deficient mice by impairing anti-inflammatory responses and IL-10 production.

bioRxiv · Aug 6, 2021 · PreprintImmunology

Development of Small Molecule Inhibitors Targeting PBX1 Transcription Signaling as a Novel Cancer Therapeutic Strategy

T.-L. Wang, I.-M. Shih, Y.-A. Shen, J. Jung, G. D. Shimberg, F.-C. Hsu, Y. S. Rahmanto, S. L. Gaillard, J. Hong, J. Bosch, C.-M. Chuang

This study develops small molecule inhibitors targeting PBX1 transcription signaling, showing they suppress cancer cell growth and re-sensitize resistant tumors.

bioRxiv · Apr 19, 2021Pathology